ESR1 and breast carcinoma: Nonetheless, our study serves as a robust pre-clinical report uncovering mechanistic insights into ESR1 mutations and their roles in conferring basal-like feature to ER+ breast cancer and implicates the immune therapeutic vulnerabilities to this subset of patients.